Trials / Approved For Marketing
Approved For MarketingNCT01825395
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3, 4-Diaminopyridine |
Timeline
- First posted
- 2013-04-05
- Last updated
- 2021-10-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01825395. Inclusion in this directory is not an endorsement.